Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Financial Results

Vivani Medical Reports Positive SLIM-1 Trial Results for Semaglutide Weight Loss Implant

Vivani Medical announced positive top-line results from its SLIM-1 Phase 1 trial, demonstrating that its NPM-139 semaglutide implant is well-tolerated and effective for weight loss. The trial showed that the miniature implant achieved results comparable to weekly Wegovy injections with a superior tolerability profile.

Medicine, pacemaker, cardiac pacemaker, old. Stock photo illustrating Vivani Medical's financial results story.
Vivani Medical, Inc. · Healthcare · Photo: ulleo / Pixabay

Key highlights

  • NPM-139 achieved 0.79% weight loss over four weeks vs 0.82% for the Wegovy control group
  • Zero treatment-related adverse events reported in the implant group vs 50% in the injectable group
  • Pharmacokinetic data showed peak drug exposure at 16 days for the implant vs 2.4 days for injections
  • Vivani reported a Q3 2026 cash balance of $18.4 million to support ongoing clinical development
  • Company plans to advance NPM-139 to a Phase 2 dose-ranging weight maintenance trial in 2027

Phase 1 Clinical Outcomes

Vivani Medical (NASDAQ: VANI) released top-line results from its SLIM-1 Phase 1 clinical trial, evaluating the miniature semaglutide implant NPM-139. The four-week study conducted in Australia involved 20 GLP-1 naive participants, comparing the implant to a starting dose of Wegovy injections. Results indicated that NPM-139 was well-tolerated with zero treatment-related adverse events, whereas 50% of the Wegovy group experienced gastrointestinal issues. Pharmacokinetic data revealed a gradual increase in drug exposure, with peak levels reached at 16 days. Weight loss outcomes were nearly identical, with the implant group losing 0.79% of body weight compared to 0.82% in the injectable control.

Strategic Implications for GLP-1 Therapy

  • Demonstrates the feasibility of proprietary NanoPortal technology for continuous long-term drug delivery
  • Provides a therapeutic off-ramp via implant removal for patients requiring immediate discontinuation
  • Addresses medication non-adherence by replacing frequent injections with twice-yearly administration
  • Validates the safety profile required to initiate a Phase 2 dose-ranging trial in 2027

CEO on Future Momentum

“Roughly half of patients don’t take their medications for chronic diseases as prescribed, and GLP-1 therapies are no exception. With NPM-139, we are designing a novel GLP-1 therapy that a patient could receive once or twice a year during a routine primary care visit.”

Adam Mendelsohn, PhD, CEO, Vivani Medical

Financial Position and Pipeline Development

For the third quarter of 2026, Vivani reported a net loss of $5.8 million, or $0.09 per share, while maintaining a cash position of $18.4 million. The company is currently managing multiple strategic initiatives, including a non-exclusive agreement with Novo to evaluate NPM-139 and the pending merger of its Cortigent subsidiary with ClearOne. This merger aims to establish Cortigent as a standalone entity trading under the ticker CRGT, focused on neurostimulation. The company's current valuation and capital reserves are directed toward advancing its ultra-long-acting implant portfolio through mid-stage clinical milestones.

Vivani Medical, Inc. share price · last month
Line chart of Vivani Medical, Inc.'s share price over the last month, from $1.12 on 19 Oct → $1.02 on 16 Nov; our story on 12 Nov at $1.13.

Down 9.7% since our story on 12 Nov: $1.13 when we broke it → $1.02 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$1.12
20 Oct$1.12
21 Oct$1.16
22 Oct$1.09
23 Oct$1.11
26 Oct$1.13
27 Oct$1.14
28 Oct$1.14
29 Oct$1.14
30 Oct$1.09
2 Nov$1.09
3 Nov$1.05
4 Nov$1.07
5 Nov$1.04
6 Nov$1.07
9 Nov$1.12
10 Nov$1.15
11 Nov$1.13
12 Nov$0.98
13 Nov$1.01
16 Nov$1.02

Management commentary

“The third quarter and recent weeks mark a period of strong progress and forward momentum for Vivani. The top-line SLIM-1 results will be announced this week. We look forward to sharing those results with shareholders, industry peers, and the broader community of physicians and patients seeking less frequent dosing and the promise of potential improvements in convenience, medication adherence, and tolerability associated with GLP-1 therapies on the market and in clinical-stage development.”

Adam Mendelsohn, PhD, CEO
Vivani Medical, Inc. · financial snapshot
Share price$1.13
Market cap$102M
1-month price change-5.04%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Vivani Medical, Inc. announcing top-line results from its SLIM-1 Phase 1 clinical trial.

Read the filing ↗

Track Vivani Medical, Inc. live

Get the next Vivani Medical, Inc. SEC filing seconds after it lands.

More in Results & Earnings

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.